NDA 214487 · Chemocentryx
Tavneos
Avacopan · Oral · Complement 5a Receptor Antagonist
NovelOrphanCDER novel approval, Oct 7, 2021: To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids
Last checked: Nov 20, 2026Latest source record: Jun 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Oct 7, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
4 Phase 3, 6 recruiting
FAERS reports
6,762
5,036 serious, 691 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 2, 2026.
TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. TAVNEOS is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. ( 1 )
Mechanism: Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration. The precise mechanism by which avacopan exerts a therapeutic effect in patients with ANCA-associated vasculitis has not been definitively established.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 7, 2021 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelMedication Guide
1 products under this application
- TAVNEOS · AVACOPAN 10MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avacopan" as an intervention, any sponsor and status, largest first.
- Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03852472 · 435 participants · Start Dec 21, 2018 · Primary completion Jan 14, 2021
Drug: Avacopan · For: Hidradenitis Suppurativa; Acne Inversa
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 91 sites in all
- A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated VasculitisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT02994927 · 331 participants · Start Mar 15, 2017 · Primary completion Sep 7, 2019
Drug: Avacopan; Prednisone and 3 more · For: ANCA-Associated Vasculitis
Sites: Huntsville, Alabama; Phoenix, Arizona; Los Angeles, California · 198 sites in all
- A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT06072482 · 300 participants (planned) · Start Feb 7, 2024 · Primary completion Dec 31, 2036
Drug: Avacopan; Placebo and 1 more · For: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Sites: Anchorage, Alaska; Scottsdale, Arizona; Surprise, Arizona · 82 sites in all
- Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisPivotal-lookingRecruiting
Chiba UniversityAcademic, hospital or other
NCT06611696 · 160 participants (planned) · Start Nov 15, 2024 · Primary completion Mar 31, 2027
Drug: Avacopan, prednisolone and rituximab; Prednisolone and rituximab · For: ANCA Associated Vasculitis (AAV)
Sites: Toyoake, Japan; Asahi, Japan; Chiba, Japan · 22 sites in all
- Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney InvolvementPivotal-lookingNot yet recruiting
University Hospital, ToulouseAcademic, hospital or other
NCT07373262 · 130 participants (planned) · Start Mar 1, 2026 · Primary completion Mar 1, 2030
Drug: Avacopan; Placebo · For: ANCA-Associated Vasculitis (AAV)
Sites: Amiens, France; Angers, France; Besançon, France · 30 sites in all
AmgenAmgen (AMGN)
NCT05988008 · 80 participants · Start Oct 23, 2017 · Primary completion Jan 26, 2018
Drug: CCX168; Placebo · For: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Sites: Sumida City, Japan
- A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated VasculitisCompleted
AmgenAmgen (AMGN)
NCT01363388 · 67 participants · Start Sep 2011 · Primary completion Oct 2015
Drug: Placebo; CCX168 · For: Vasculitis
Sites: Feldkirch, Austria; Innsbruck, Austria; Linz, Austria · 44 sites in all
AmgenAmgen (AMGN)
NCT05988034 · 58 participants · Start Nov 8, 2019 · Primary completion Jan 22, 2020
Drug: Avacopan; Moxifloxacin and 2 more · For: Electrocardiography
Sites: Tempe, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hospitalisation1,026
- death414
- off label use373
- therapy interrupted354
- diarrhoea272
- fatigue270
- nausea249
- pneumonia245
- headache183
- covid-19176
- product dose omission issue158
- dialysis145
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 8 |
| 2022 | 462 |
| 2023 | 1,671 |
| 2024 | 1,242 |
| 2025 | 1,727 |
| 2026 | 1,652 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tavneos (Avacopan)
2024 spending
$76.0M
Beneficiaries
828
4,746 claims
Per beneficiary
$91,847
$89.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $195,550 |
| 2022 | $11,726,921 |
| 2023 | $33,951,025 |
| 2024 | $76,049,420 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. · Ann Rheum Dis 2024 · Systematic Review
- Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW, Bruchfeld AN, Harper L, et al. · J Am Soc Nephrol 2017 · Multicenter Study, Randomized Controlled Trial
- Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C, Kopelman H, Zaino M, et al. · Ann Pharmacother 2023 · Systematic Review
- Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D, Dua A, Yue H, et al. · Ann Rheum Dis 2024 · Randomized Controlled Trial
- Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy: Randomized, Double-Blind Clinical Trial.
Bomback AS, Herlitz LC, Kedia PP, et al. · J Am Soc Nephrol 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Chemocentryx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.